Regulatory Approval

SERB Pharma's acquisition of Idefirix® rights offers new hope to thousands of highly sensitized patients previously unable to receive a kidney transplant.

Mineralys Therapeutics' lorundrostat shows promise for millions with uncontrolled blood pressure and kidney disease, targeting a key hormonal driver.

A new scholarship champions empathy in medicine, founded by a doctor whose own license has recently come under emergency suspension by state regulators.

NEXT Investors' Series A in Transient.AI signals a shift to secure, auditable AI, aiming to solve the trillion-dollar compliance challenge in finance.

Amid rising global threats, a new AI and drone-based platform aims to modernize the protection of nuclear power plants for a new era of energy expansion.

A strategic investment from Olayan Financing Company positions MS Pharma to dominate the MENA biologics market, fueling Saudi Arabia's Vision 2030 goals.

Philippine fintech giant Mynt reports a 120% quarterly profit surge, fueled by explosive growth in lending, investments, and international expansion.

Industry veteran Steve Motes joins Tulyp Medical as CEO, aiming to commercialize a revolutionary pressure-driven perfusion system with a proven team.

The life sciences news hub earned prestigious Neal and Azbee National Gold awards, highlighting the growing influence of expert-driven B2B journalism.

New data reveals TARA-002 has a 55% complete response rate at one year for NMIBC, offering a promising, safer alternative to standard care.

Glucotrack seeks FDA trial approval for its revolutionary 3-year implantable glucose monitor, racing against financial clocks to change diabetes care.

The biotech firm is set to launch its first commercial products, using an innovative strategy to tackle long-neglected markets in women's healthcare.

A key workshop aims to bridge the gap between FDA policy and patient needs, seeking to streamline therapy development for millions with rare diseases.

Senti Biosciences advances its AML cell therapy to a registrational trial after FDA meeting and a key discovery that quadruples patient response rates.

With a major new financing round, BlueWind Medical is set to expand access to its innovative Revi® System for urgency urinary incontinence.

The biopharma posts record Q1 revenue and profit, driven by its flagship DefenCath and a key acquisition, while a promising pipeline signals future growth.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

A new partnership aims to solve the massive underdiagnosis of a severe genetic disorder by offering free testing, a move with deep strategic implications.

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

With a novel drug for schizophrenia and deep financial backing, LB Pharmaceuticals is advancing a promising new therapy for complex mental illnesses.